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Background: Maternal vaccines against pertussis are not yet recommended in the developing world.
Besides unclear burden estimates, another concern is that transplacental transfer of maternal pertussis
antibodies could result in attenuation of the immune response to whole cell pertussis (DTwP) primary
vaccination series in infants. This study was taken up to determine whether higher levels of maternal per-
tussis antibodies attenuate immune response of infants to DTwP vaccination series given at 6–10–
14 weeks of age.
Methodology: A total of 261 pregnant women and their infants from four low-income settlements in
Karachi, Pakistan were enrolled in this study. The study endpoints were infant antibody titers for
Pertussis toxin (PTx), Filamentous hemagglutinin antigen (FHA), Pertactin (PRN) and Fimbriae type 2/3
(FIM) – from birth through 18 weeks of age. Cord blood or pre-vaccine pertussis antibody titers indicate
the concentration of maternal antibodies transferred to infants. Linear regression models were used to
determine the association between higher maternal antibody titers and infant immune response to
DTwP vaccine. Geometric Mean Ratio (GMR) was calculated as the ratio of infant antibody titers at spec-
ified time points against the maternal antibody titers at the time of delivery.
Results: At eighteen weeks of age, the adjusted b regression coefficient for PTx was 0.06 (95% CI: -0.49-
0.61), FHA 0.02 (95% CI: -0.26 -0.29), PRN 0.02 (95%CI -0.38- 0.43), and FIM 0.17 (95%CI: -0.21-0.54).
Among infants who received at least two doses of DTwP vaccine, higher maternal antibody titers did
not have any attenuating effect on infant post-immunization antibody titers against all four pertussis
antigens.
Conclusion: Maternal pertussis antibodies did not attenuate infant’s immune response to pertussis anti-
gens in DTwP primary vaccine given at 6–10–14 weeks of age.
 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Most childhood primary Diphtheria, Tetanus and whole cell
Pertussis (DTwP) vaccination series in low-and-middle-income
countries (LMICs) follow the 6, 10, and 14 weeks immunization
schedule [1]. Infants too young to be completely vaccinated are
not adequately protected until they are several months old and
therefore are more susceptible to acquiring infections, such as per-
tussis [2]. Maternal vaccination against pertussis during pregnancy
can address this immunity gap in young infants through transpla-
cental transfer of maternal pertussis antibodies. In addition,
prevention of pertussis in the mother may potentially offer protec-
tion to the infant from acquiring pertussis in early infancy. Even
though pertussis vaccine as Tdap is recommended for pregnant
women in both the UK and the US, it is not part of routine antenatal
care in developing countries where the burden of pertussis is likely
to be much higher [5,6].
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There is a concern that the transplacental transfer of maternal
pertussis antibodies to the infant could result in attenuation of
immune response to the primary childhood pertussis vaccination
series, also known as ‘‘blunting”. Several studies have examined
the risk of blunting among infants receiving the acellular pertussis
vaccine. However these results have not been conclusive [7,8].
There are fewer studies assessing the risk of blunting among
infants that receive the whole cell pertussis vaccine [4,9]. A study
conducted by Englund et al. showed attenuation of immune
response to whole-cell pertussis vaccine administered among
infants (2–4–6 months) born to mothers with high pertussis
maternal antibody titers [4].
However, no studies to date have assessed the impact of mater-
nal antibody titers on pertussis response in DTwP vaccination ser-
ies administered at 6–10–14 weeks, the schedule used most
commonly in LMICs, and covering a majority of the world’s birth
cohort. In this study, we assess the impact of pertussis maternal
antibodies (acquired from childhood pertussis immunization or
pertussis infection) on the DTwP immune response in infants that
received primary vaccination series given at 6–10–14 weeks of age.
2. Methodology
2.1. Surveillance
The Prevention of Pertussis in Young Infants in Pakistan (PrePY)
Baseline Surveillance study was conducted from February 2015 to
August 2016 in four low-income settlements of Karachi, Rehri
Goth, Ibrahim Hyderi, Bhains colony, and Ali Akbar Shah. The
Department of Pediatrics and Child Health of the Aga Khan Univer-
sity Hospital (AKUH) has been operating primary healthcare cen-
ters in these areas with active demographic surveillance system
for several years. We registered 261 healthy, pregnant women ran-
domly on or after 27 weeks of gestation or mothers who gave birth
within 72 h prior to registration. Few subjects were lost to follow-
up to reasons such as refusal for blood draw after delivery, molar
pregnancy, still birth, death after delivery and refusal to continue
in the study (Fig. S3). Baseline maternal characteristics (age, educa-
tion, antenatal care, TT vaccination, body mass index and hyper-
tensive status) were collected at the time of enrollment. Since it
is not recommended in LMICs, mothers were not vaccinated with
TDaP during pregnancy. Infants born to these mothers were fol-
lowed from birth through eighteen weeks of age. Baseline infant
characteristics (gender, gestational age, weight, and head circum-
ference) were collected at the time of delivery. Infant DTwP vacci-
nation status was obtained at the 6th, 10th and 14th weeks after
delivery. The surveillance methods have been previously described
in detail [2].
2.2. Blood specimen collection
One blood draw (7 mL) was made from the enrolled mothers
within 72 h of delivery. Three blood specimens were collected from
the infants. The first blood specimen was collected at birth (cord
blood) or within 72 h of delivery via a venipuncture. The second
blood specimen from infants was collected at 6 weeks of age (prior
to receipt of first dose of DTwP) and the third blood specimen was
collected at 18 weeks of age. Approximately 3 mL of blood from
infants was collected each time. Blood specimens were collected
by a trained phlebotomist.
After collection, blood samples were transported to the Infec-
tious Disease Research Laboratory at the AKUH under cold chain
maintenance. Sera were separated at the laboratory and stored in
cryovials at 80 C. The sera were transported under appropriate
cold-chain management, to the Microbial Pathogenesis and
Immune Response (MPIR) Laboratory, Centers for Disease Control
and Prevention (CDC), Atlanta USA for testing.
2.3. Laboratory procedures
Serum samples were analyzed for antibodies against PTx, PRN,
Fim2/3 and FHA using a microsphere based multiplex antibody
capture assay (MMACA). Each assay plate included a pertussis
human standard reference serum, WHO 06/140, diluted 4-fold for
8 dilutions starting at 1/20; and an internal quality control (QC)
serum, WHO 06/142, diluted 2-fold for 4 dilutions starting at
1/400. Test serum samples were diluted 2-fold for 7 dilutions start-
ing at 1/50. IgG-free human serum (Sigma, St. Louis, MO, USA), and
assay buffer blanks were included in each assay plate as reagent
controls. Replicates were maintained for standard, QC serum and
blanks. All QC, reference standard and sample dilutions were car-
ried out in a 96-well round bottom titer plate (CLS3799, Sigma,
St. Louis, MO). A 96-well multiscreen HTS filter plate (MABVN1250,
Millipore Corp, Billerica, MA) pre-wet with 100 lL assay buffer
(0.1% BSA (wt/vol) in PBS) was aspirated and 25 lL/well of pertus-
sis antigen-conjugated microspheres (multi-plex; 2500 micro-
spheres/region/well) were transferred. From the dilution plate,
25 lL reference standard, QCs and serum samples were transferred
to the filter plate with microspheres and incubated in dark for
40 ± 10 min at RT with 150 RPM agitation in a horizontal orbital
agitator. The plate was aspirated and washed 3 times with
100 lL assay buffer. To each well, 50 lL of a 1/200 dilution of R-
PE conjugated Goat anti-human Fcc specific IgG (GTIGF-001, Moss
Inc. Pasadena, MD) in PBS was added and incubated in dark for
20 ± 10 min at RT with 150 RPM agitation in a horizontal orbital
agitator. The plate was aspirated, washed 3 times with 100 lL
assay buffer and the microspheres were resuspended in 130 lL
assay buffer. The plate was read in a Luminex 200 reader (Luminex
Corp, Houston, TX) and the data analyzed for the antibody concen-
tration using a SAS version 9.3 (SAS Institute Inc, Cary, NC) running
a MMACA customized endpoint calculation algorithm. The reporta-
ble value (RV) of the assay is the mean of two independent tests
and expressed as the serum concentration of anti-pertussis anti-
gens specific IgG in IU/mL.
2.4. Statistical analysis
The primary outcomes were antibody titers for four pertussis
antigens (PTx, FHA, PRN and FIM) in cord blood and infant serum
at birth, at six weeks, and at eighteen weeks. Geometric mean con-
centration (GMC) with 95% confidence interval was computed,
stratified by DTwP vaccine dose, for all pertussis antigens at spec-
ified time points. Geometric Mean Ratios (GMR) with 95%CI were
calculated to compare the antibody titer of infants at each time
point (birth, 6 weeks and 18 weeks) to the maternal antibody titer
at delivery. Half-lives of all pertussis antibodies were determined
in unvaccinated control infants.
Crude and multivariable linear regression models were used to
determine the impact of higher maternal antibody titers, at the
time of delivery, on infant vaccine response at specified time
points. The multivariable model adjusts for birth weight, gesta-
tional age (determined from date of last menstrual period as
reported by pregnant mothers) and gender. All infants who
received at least 2 doses of DTwP vaccine were included in this
analysis. Both maternal and infant antibody concentrations were
log2-transformed and maternal antibody titers were included in
the model as a continuous variable. The regression coefficient, b,
from this model and their 95%CIs were presented as the measure
of association between infant antibody titers at the specified time
point (birth, 6 weeks and 18 weeks) to maternal antibody titers at
delivery. Where negative b regression coefficients imply that infant
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antibody titers decline with increasing maternal antibody levels at
delivery, positive numbers imply that infant antibody titers
increase with increasing maternal antibody levels at delivery and
null values (b=0) imply no association between infant and mater-
nal antibody titers at delivery. For comparison, sensitivity analysis
was conducted using dichotomized (above and below median)
maternal antibody titers keeping below median as the reference
category.
Approval from Ethical Review Committee/Institutional Review
Boards of the AKU, Emory University, and Centers for Disease Con-
trol Prevention as well as written informed consent from the study
subjects, was obtained before commencement of this study.
3. Results
A total of 261 healthy, pregnant women in their third trimester
of pregnancy met the eligibility criteria and were included in the
current study. Serum samples for serologic analysis were collected
from 219/261 (83.9%) pregnant women within 72 h of delivery.
Table 1 summarizes the baseline maternal characteristics of the
pregnant women in our study cohort. Maternal age was 26 years,
on average with almost two-thirds of mothers having no formal
education. Approximately 3% of the mothers were underweight
(BMI < 18.5) and only 2% were hypertensive at the time of
enrollment.
In this study, a total of 222 infants were followed from birth
until the end of study follow-up (i.e. 18 weeks of age). Serum sam-
ples for serologic analysis were collected from 206/222 (93%)
infants at birth (cord/serum samples), 133/222(60%) after six
weeks and 143/222 (64%) infants after 18 weeks. Table 2 summa-
rizes the baseline characteristics of the infants followed until the
end of study period. In our study cohort, the mean (SD) gestational
age at birth was 34.6 (4.4) weeks. Almost half of all infants were
boys and the mean (SD) birth weight in kilograms (kg) of infants
in our study cohort was 2.8 (0.4). There was no significant differ-
ence in infant antibody titers between infants whose first blood
specimen was collected at birth (cord blood) and infants whose
first blood specimen was collected within 72 h of delivery via a
venipuncture (p = 0.259, Table S9).
Approximately 70% of the infants received at least one dose of
DTwP vaccine whereas 45% and 12.5% of the infants were reported
to have received two doses and all three doses of DTwP vaccine
respectively, at 6–10–14 weeks of age. There were no significant
differences in demographic characteristics between infants who
received at least one, two or three doses of DTwP (Tables S7, S8).
There was some variation in the age at which infants received each
dose of DTwP, however overall vaccine doses were given within
recommended age range (Table S10).
Geometric mean ratios indicate that maternal antibody titers at
delivery did not blunt infant vaccine response, among infants who
received at least two doses of DTwP vaccine, for all pertussis anti-
gens (PTx, FHA, PRN and FIM, Table 3). In the adjusted model
(adjusting for gestational age at birth, gender and birth weight),
we observed that infant antibody titers increase significantly with
increasing maternal antibody levels at delivery against all pertussis
antigens (PTx, FHA, PRN and FIM) at birth and at six weeks
(Table 4). Breastfeeding status was not included in the multivari-
able model because it had no meaningful effect on the outcomes
of interest (Tables S5, S6). Also, limiting to infants who received
Table1
Baseline maternal characteristics of pregnant women in the study.
Maternal characteristics Mean ± SD or N (%)
Maternal age
16–20 years 50 (19.2)
21–25 years 82 (31.4)
26–30 years 75 (28.7)
>30 years 54 (20.7)
Mean ± SD 26.4 ± 5.8
n 261
Maternal education
No formal education 174 (66.7)
Formal education received 87 (33.3)
n 261
ANC
None 118 (45.2)
1 13 (5)
2 21 (8.1)
3 26 (10)
>3 83 (31.8)
n 261
ANC skilled provider
Any skilled provider 93 (85.3)
Others 16 (14.7)
n 109
TT vaccines doses
None 94 (36)
1 84 (32.2)
2 81 (31)
3 2 (0.8)
N 261
Body Mass Index*
Underweight 7 (3.8)
Normal 75 (40.5)
Overweight/Obese 103 (55.7)
n 185
Hypertension
Yes 4 (2.1)
No 191 (98)
n 195
Note: Maternal education was assessed in terms of the number
of completed years of schooling, where if a woman ever attended
school she was categorized as received a formal education and if
she did not receive any years of schools she was categorized as
No Formal Education.
Abbreviations: ANC = Antenatal care, TT = Tetanus Toxoid.
* BMI cutoffs were defined as follows: Underweight
(BMI < 18.5), Normal (BMI 18.5-25), Overweight (BMI > 25).
Table 2
Baseline characteristics and vaccination status of infants until the end of study follow-
up (18 weeks).
Infant characteristics Mean ± SD or N (%)
Gender
Male 121 (54.3)
Female 102 (45.7)
n 223
Age at first blood draw (days)
Mean ± SD 2.2 ± 3.4
n 200
Weight (Kg)
Mean ± SD 2.8 ± 0.4
n 218
Length (cm)
Mean ± SD 47.9 ± 3.7
n 204
Head circumference (cm)
Mean ± SD 33.2 ± 1.7
n 205
Vaccination status*
DTwP 1 dose 163 (73.2)
DTwP 2 doses 101 (45.1)
DTwP 3 doses 28 (12.5)
DTwP (at least one dose) 163 (73.2)
n 215
* Infants were vaccinated according to the EPI 6–10–14 week immunization
schedule.
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at least two doses of DTwP vaccine, higher maternal antibody titers
did not have a significant effect on infant post-immunization
(18 weeks) antibody titers, against all pertussis antigens (PTx,
FHA, PRN and FIM) in the adjusted model. These results were con-
firmed when maternal antibody titers were modeled as a binary
variable (above or below median- keeping below median as the
reference category, Table S2).
Table S1 lists the geometric mean concentrations (GMC) of all
pertussis antigens (PTx, FHA, PRN and FIM), according to time of
sampling and infant vaccination status. Our results demonstrated
significantly higher GMCs for all pertussis antigens (except FIM)
at 18 weeks in those who received at least two doses of DTwP vac-
cine as per WHO recommended 6–10–14 week EPI vaccination
schedule used in LMICs- compared to unvaccinated (Fig. S1). We
found that in unvaccinated infants, the half-life of antibodies
against PTx and FHA pertussis antigens was approximately six
weeks (Fig. 1). However, given the data, the half-life of antibodies
to FIM and PRN antigens were not clear (Fig. 1).
4. Discussion
We assessed whether higher maternal pertussis antibody titers
attenuate vaccine response to childhood DTwP primary vaccina-
tion series (6–10–14 week immunization schedule) in young
infants in a low income setting. We found no association between
higher maternal pertussis antibody titers and post-immunization
(18 weeks) pertussis antibody titers in infants who had received
at least two doses of DTwP vaccine. Further, this study demon-
strated that higher maternal antibody titers significantly increased
infant antibody titers at birth and at six weeks. While infant
antibody titers decreased at 18 weeks, this change was small and
not significant. We observed that the estimated duration of half-
life of the maternally transferred antibody against the pertussis
antigens PTx and FHA were approximately six weeks. Likewise, a
study conducted by Van Savage et al. demonstrated that the dura-
tion of half-life of maternally transferred antibody against PTx and
FHA pertussis antigens was around six weeks [3].
Table 4
Association between maternal antibody titers (at the time of delivery) and infant antibody titers as measured by linear regression coefficient, b, with 95% CIs for children who
received at least two doses (n = 129) of DTwP vaccine, per pertussis antigen at various time points in both unadjusted and adjusted (adjusted for birth weight, gestational age and
gender) linear regression models.
Regression coefficients
(a,b) with 95%
confidence interval & P-values***
Unadjusted model Adjusted model
At Birth At 6 weeks At 18 weeks At Birth At 6 weeks At 18 weeks
PTx
a (95% CI)* 0.12 (0.32, 0.57) 1.43 (1.96, 0.9) 2.75 (1.38, 4.13) 2.32 (0.62, 5.26) 0.46 (2.95, 3.87) 10.3 (1.99, 18.6)
p-value 0.5834 <0.0001 0.0001 0.1204 0.7893 0.0161
b (95%CI)** 0.83 (0.67, 0.99) 0.9 (0.71, 1.09) 0.14 (0.37, 0.64) 0.79 (0.61, 0.98) 0.81 (0.58, 1.05) 0.06 (0.49, 0.61)
p-value <0.0001 <0.0001 0.5863 <0.0001 <0.0001 0.8293
FHA
a (95% CI)* 0.68 (0.32, 0.57) 0.33 (1.96, 0.9) 2.86 (1.38, 4.13) 3.52 (1.5, 5.55) 2.46 (0.72, 5.64) 3.84 (0.18, 7.87)
p-value 0.0172 0.4064 <0.0001 0.0009 0.1272 0.0608
b (95%CI)** 0.86 (0.74, 0.99) 0.83 (0.66, 1) 0.14 (0.1, 0.37) 0.75 (0.61, 0.88) 0.73 (0.52, 0.94) 0.02 (0.26, 0.29)
p-value <0.0001 <0.0001 0.2512 <0.0001 <0.0001 0.9084
PRN
a (95% CI)* 1.22 (1.79, 0.66) 1.61 (2.2, 1.02) 3.08 (2.07, 4.08) 0.97 (2.59, 4.54) 0.23 (3.76, 4.22) 4.04 (2.09, 10.16)
p-value <0.0001 <0.0001 0.1757 0.5881 0.9086 0.1919
b (95%CI)** 1.03 (0.84, 1.23) 0.83 (0.63, 1.03) 0.23 (0.11, 0.57) 0.91 (0.68, 1.14) 0.79 (0.53, 1.05) 0.02 (0.38, 0.43)
p-value <0.0001 <0.0001 0.1757 <0.0001 <0.0001 0.9166
FIM
a (95% CI)* 0.12 (0.4, 0.64) 0.45 (0.93, 0.03) 4.23 (3.28, 5.19) 1.77 (2.71, 6.25) 0.53 (3.38, 4.44) 5.91 (1.78, 13.59)
p-value 0.6446 0.0659 <0.0001 0.4322 0.7871 0.1293
b (95%CI)** 0.88 (0.72, 1.04) 0.74 (0.59, 0.89) 0.04 (0.27, 0.35) 0.88 (0.67, 1.09) 0.66 (0.48, 0.85) 0.17 (0.21, 0.54)
p-value <0.0001 <0.0001 0.1757 <0.0001 <0.0001 0.9166
Note: Linear regression models using the log2 transformed antibody titers were used to determine the impact of maternal titers at the time of delivery on infant vaccine
response at specified time points.*a is the regression intercept. ** Negative b coefficients imply that infant antibody titers decline with increasing maternal antibody levels at
delivery, positive numbers imply that infant antibody titers increase with increasing maternal antibody levels at delivery and a b coefficient of zero indicates no association
between infant antibody titers and maternal antibody levels at delivery. ***P-value < 0.05 was considered significant. Abbreviations: FHA = Filamentous hemagglutinin,
FIM = Fimbriae type 2/3, PRN = Pertactin, and PTx = Pertussis toxin.
Table 3
GMR with 95% CI-for children who received no doses and for children who received at least two doses of DTwP vaccine, per pertussis antigen at birth and at 6 and 18 weeks of age.
Geometric Mean Ratio (GMR) Unvaccinated Vaccinated
At Birth At 6 weeks At 18 weeks At Birth At 6 weeks At 18 weeks
PTx
GMR (95%CI) 0.77 (0.62, 0.96) 0.36 (0.26, 0.49) 0.21 (0.07, 0.6) 0.83 (0.69, 1.01) 0.32 (0.26, 0.39) 1.9 (1.01, 3.58)
FHA
GMR (95%CI) 1.01 (0.82, 1.25) 0.42 (0.32, 0.56) 0.15 (0.08, 0.28) 1.07 (0.93, 1.24) 0.48 (0.4, 0.59) 0.62 (0.44, 0.89)
PRN
GMR (95%CI) 0.54 (0.42, 0.69) 0.38 (0.25, 0.55) 0.47 (0.19, 1.17) 0.45 (0.36, 0.57) 0.25 (0.19, 0.32) 2.42 (1.51, 3.89)
FIM
GMR (95%CI) 0.78 (0.62, 0.99) 0.51 (0.3, 0.87) 2.96 (0.79, 11.12) 0.91 (0.69, 1.19) 0.49 (0.38, 0.64) 5.08 (2.76, 9.36)
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Previous studies have reported varying associations between
higher maternal antibody titers and attenuation of infant vaccine
response. A study conducted by Englund et al. [4], found higher
levels of pre-existing maternal antibody titers against PTx were
associated with substantial reductions in the post-immunization
titers among infants who had received three doses of DTwP (2–
4–6 months immunization schedule) [4]. In contrast, our findings
demonstrate that the infant (PTx) response to DTwP vaccine was
not adversely affected in the presence of higher levels of maternal
antibody titers. One major difference is Englund et al. assessed
infant immune responses among those who received 3 doses of
DTwP vaccine while our study assessed infant immune response
among those who received at least 2 doses of the DTwP vaccine.
In addition, a meta-analysis conducted by Voysey et al. [8] found
significant blunting of infant vaccine response to DTaP-
specifically against PTx, FHA and PRN pertussis antigens- among
infants born to mothers who received acellular pertussis vaccina-
tion during pregnancy. Despite the differences in DTwP primary
immunization schedules (6–10–14 weeks versus 2–4–6 months),
both our study and the study conducted by Englund et al. [4], sup-
port the introduction of comprehensive pre-natal immunization
programs which could potentially result in the closure of the sus-
ceptibility gap for pertussis in young infants.
Our results are consistent with those obtained from a random-
ized controlled trial conducted in Vietnam [10], which demon-
strated no blunting of immune response against PTx and FHA
pertussis antigens in infants who received DTaP vaccine (2–3–
4 months primary immunization schedule) in the presence of
higher maternal antibody titers obtained from mothers who were
vaccinated with DTaP during pregnancy. However, the type of per-
tussis vaccine used (acellular pertussis vaccine versus whole-cell
pertussis vaccine) and the dosing schedule (2–3–4 months versus
6–10–14 weeks) were different between these two studies.
There are several strengths in our study which merit mention.
First, we followed a large cohort of infants closely over an eighteen
week period of follow-up, which was a challenging task in a devel-
oping country setting. Second, we included potential confounding
factors such as gestational age, gender and birth weight in our
adjusted model. Finally, the present study is the first to describe
the impact of high maternal antibody titers on infant immune
response to DTwP vaccine (6–10–14 week immunization sched-
ule), used in LMICs.
Fig. 1. Geometric mean concentrations (GMC) with 95% confidence interval (CI) of infant pertussis antibody titers and their half-lives for infants who did not receive any
vaccination. Abbreviations: FHA = Filamentous hemagglutinin, FIM = Fimbriae type 2/3, PRN = Pertactin, and PTx = Pertussis toxin. Note: I bars indicate 95% CIs. (— one half
infant antibody titer at birth). Outliers (defined as greater than two standard deviations from the mean, n = 1) were excluded (See Fig. S2 for GMC with 95% confidence
intervals with outliers included). Birth = Infant cord blood/sera (n = 55); 6 (n = 18) and 18 weeks (n = 19) = Infant sera.
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We were limited by the lack of maternal history regarding par-
ity, childhood DTwP vaccination status and exposure to pertussis
disease. Few subjects were lost to follow-up due to reasons such
as refusal for blood draw after delivery, molar pregnancy, still
birth, death after delivery and refusal to continue in the study.
Despite this, subject retention and follow- up in our study was suf-
ficient to provide required statistical strength to draw comprehen-
sive conclusions.
In summary, we found no blunting association between higher
pertussis maternal antibody titers and infant immune response
to childhood DTwP vaccine given at 6–10–14 weeks of age in
LMICs.
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Author summary
Maternal vaccines against pertussis are not yet recommended
in the developing world due to unclear burden estimates and pos-
sible infant vaccine response attenuation by maternal antibodies.
Our findings suggest that maternal pertussis antibodies do not
attenuate serologic response in infants to pertussis (DTwP) pri-
mary vaccination series.
Appendix A. Supplementary material
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.vaccine.2018.09.045.
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